🔮 Better than the Oracle? Our Fair Value found this +42% bagger 5 months before Buffett bought itRead More

Icahn to send letter to oppose Cigna-Express Scripts deal: WSJ

Published 08/06/2018, 08:17 PM
Updated 08/06/2018, 08:20 PM
© Reuters. FILE PHOTO: Carl Icahn gives an interview on FOX Business Network's Neil Cavuto show in New York
ESRX
-
AMZN
-
CI
-

(Reuters) - Investor Carl Icahn will send an open letter to the shareholders of insurer Cigna Corp (N:CI) asking them to vote against the company's $52 billion Express Scripts Holding Co (O:ESRX) buyout, the Wall Street Journal reported on Monday, citing a draft of the letter.

Icahn and his affiliates own about 0.56 percent of Cigna, which is worth over $250 million as of Monday's market close, the Journal reported, citing people familiar with the matter. https://on.wsj.com/2voopWB

"Cigna is dramatically overpaying for a highly challenged Express Scripts that is facing existential risks on several fronts," said the letter, which the newspaper reported would be made public on Tuesday.

Express Scripts spokesman Brian Henry told Reuters on Monday that the company remained confident in the deal. Cigna and a representative for Icahn did not respond to a request for comment outside regular business hours.

© Reuters. FILE PHOTO: Carl Icahn gives an interview on FOX Business Network's Neil Cavuto show in New York

Investors have expressed concern over the Cigna-Express Scripts deal because of the growing presence of Amazon.com (O:AMZN) in the healthcare sector and U.S. President Donald Trump's push to cut rebates from drugmakers to pharmacy benefit managers.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.